Home > Insider Trading > Filing (0001209191-21-055210)

Filing Details

Accession Number:: 0001209191-21-055210
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-08 19:13:11
Reporting Period:: 2021-09-07

Accepted Time:: 2021-09-08 19:13:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134657	Luke Evnin	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1473930	Todd Foley	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609492	Mpm Bioventures 2014, L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609493	Mpm Bioventures 2014 (B), L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609495	Mpm Asset Management Investors Bv2014 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1729504	Mpm Bioventures 2018 (B), L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1734817	Mpm Asset Management Investors Bv2018 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1765021	Mpm Bioventures 2014 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1765091	Mpm Bioventures 2014 Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-07	30,474	$29.18	3,635,313	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-07	31,340	$0.00	3,603,793	No	4	J	Indirect	See Footnote
Common Stock	Disposition	2021-09-08	11,152	$28.61	3,592,821	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-09-08	940	$29.10	3,591,881	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	J	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
The shares were sold as follows: 18,156 by MPM BioVentures 2014, L.P. ("BV 2014"), 625 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 11,467 by MPM BioVentures 2018, L.P. ("BV 2018") and 226 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.89 to $29.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 2,050,714 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 70,585 by AM BV2014, 1,295,187 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration.
The shares were distributed as follows: 20,848 by BV 2014(B) and 10,492 by AM BV 2018(B).
The shares are held as follows: 2,050,714 by BV 2014, 107,713 by BV 2014(B), 70,585 by AM BV2014, 1,295,187 by BV 2018, 54,213 by BV 2018(B) and 25,561 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
The shares were sold as follows: 6,644 by BV 2014, 229 by AM BV2014, 4,196 by BV 2018 and 83 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth inthis footnote.
The shares are held as follows: 2,044,070 by BV 2014, 107,713 by BV 2014(B), 70,356 by AM BV2014, 1,290,991 by BV 2018, 54,213 by BV2018(B) and 25,478 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniaryinterest therein.
The shares were sold as follows: 560 by BV 2014, 19 by AM BV2014, 354 by BV 2018 and 7 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.04 to $29.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth inthis footnote.
The shares are held as follows: 2,043,510 by BV 2014, 107,713 by BV 2014(B), 70,337 by AM BV2014, 1,290,637 by BV 2018, 54,213 by BV 2018(B) and 25,471 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniaryinterest therein.Page